sponsored
PatientsVille.com Logo

PatientsVille

Bayer Medical Research Studies

Up-to-date List of Bayer Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Bayer Medical Research Studies

Rank Status Study
1 Recruiting Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil
Condition: Occupational Health
Intervention: Behavioral: Examination and survey
Outcome Measures: Cardiovascular health metrics on a three-point scale (poor, intermediate, ideal);   Number of participants who are suggested to participate in a lifestyle change program and show up for at least one session
2 Unknown  Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.
Condition: Treatment of Episodic Tension Headache
Interventions: Drug: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965);   Drug: Aspirin - Bayer
Outcome Measures: The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.;   • Reduction of associated symptoms (photophobia, phonophobia, nausea, vomiting); • Symptoms stomach before and after treatment • Change in gastric pH after administration; • Incidence of administration of rescue medications; • Change in pain
3 Recruiting Measuring Brain Amyloid Plaque Load in Older Adults Using Bayer 94-9172 Positron Emission Tomography and X-ray Computed Tomography
Condition: Late Onset Alzheimer Disease
Intervention: Drug: BAY 94-9172 (Florbetaben)
Outcome Measure: Changes in amyloid plaque load in the brain of the course of 3 years
4 Recruiting Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
Condition: Haemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Outcome Measures: The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool;   The difference of the elimination half-life calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool;   The difference of the clearance calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool;   The dosage of factor VIII calculated by OPTIMS calculator;   The practicality of the OPTIMS calculator by a physician's satisfaction questionnaire
5 Recruiting Sorafenib Long Term Extension Program (STEP)
Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Outcome Measure: Long term safety of patients coming from completed sorafenib trials.
6 Recruiting Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934
Conditions: Anemia;   Renal Insufficiency, Chronic
Interventions: Drug: BAY85-3934;   Biological: Darbepoetin alfa
Outcome Measures: Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period;   Maintenance in hemoglobin target range (10.0 to 12.0 g/dL);   Change in hemoglobin level;   Number of patients with hemoglobin levels outside the target range;   Dose level in the evaluation period;   Duration of exposure on each dose level;   Number of subjects requiring titration of dose;   Number of participants with serious adverse events as a measure of safety and tolerability
7 Recruiting 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
Conditions: Anemia;   Renal Insufficiency, Chronic
Interventions: Drug: BAY85-3934;   Drug: Placebo
Outcome Measures: Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period;   Change in local laboratory hemoglobin level from baseline;   Speed of change in hemoglobin level per unit time;   Duration of treatment exposure;   Number of participants with serious adverse events as a measure of safety and tolerability;   Pharmacodynamics characterized by erythropoietin concentration;   Pharmacodynamics characterized by reticulocyte count
8 Not yet recruiting Long-term Pre-dialysis Extension in Europe and Asia Pacific
Conditions: Anemia;   Renal Insufficiency, Chronic
Interventions: Drug: BAY85-3934;   Biological: Darbepoetin
Outcome Measures: Change in local laboratory hemoglobin level from baseline;   Number of participants with serious adverse events as a measure of safety and tolerability;   Maintenance in hemoglobin target range (10.0 to 12.0 g/dL);   Duration of treatment exposure;   Number of subjects requiring titration of dose;   Change of reticulocyte count from baseline of this study;   Change of reticulocyte count from baseline of study 15141 or 15261;   Change of red blood cell count from baseline of this study;   Change of red blood cell count from baseline of study 15141 or 15261;   Change of hematocrit from baseline of this study;   Change of hematocrit from baseline of study 15141 or 15261;   Change of central laboratory hemoglobin level from baseline of this study;   Change of central laboratory hemoglobin level from baseline of study 15141 or 15261
9 Unknown  Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period
Condition: Contraception
Intervention: Device: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Outcome Measures: Continuation Rates of the LNG-IUS when placed postpartum at three time periods;   Expulsion rate of the LNG-IUS when placed postpartum at three time periods;   Pain at placement
10 Recruiting Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Outcome Measures: Cognitive performance as measured by SDMT (Symbol Digit Modalities Test);   Physical activity as measured by the Baecke questionnaire;   Disability as measured by EDSS (Expanded Disability Status Scale);   Fatigue as measured by FSMC (Fatigue Scale for Motor and Cognitive Functions);   Depression as measured by the CES-D (Center for Epidemiologic Studies Depression);   Quality of life as measured by the SF-12 (Mental and physical health-scale measure of quality of life)
11 Recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
Outcome Measures: Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib;   Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.;   Determination of patient's background to affect the safety and efficacy of Regorafenib using standard observational survey and follow-up survey
12 Recruiting Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)
Condition: Venous Thrombosis
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measure: Real-life medical resource use consumption based on medical examination and patient diary cards
13 Recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
Outcome Measures: Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review;   Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review;   Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators;   Disease control (central and investigator's assessment);   Overall survival;   Time to radiographic tumor progression (central and investigator's assessment);   Duration of response (central and investigator's assessment);   Time to objective response (central and investigator's assessment).;   Change in tumor size (central and investigator's assessment);   Best overall response (central and investigator's assessment);   Progression-free survival (central and investigator's assessment);   Number of participants with adverse events as a measure of safety and tolerability
14 Recruiting Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Condition: Bacterial Infections
Interventions: Drug: Tedizolid (BAY119-2631);   Drug: Placebo Tedizolid (BAY119-2631);   Drug: Linezolid;   Drug: Placebo Linezolid
Outcome Measures: Early Clinical Response;   Clinical response at the End of Treatment (EOT) Visit;   Investigator's assessment of clinical success at the Post Therapy Evaluation (PTE) Visit;   Investigator's assessment of clinical response at the 48-72 hours visit;   Investigator's assessment of clinical response at the 7 day visit;   Change from baseline in the pain scores;   Number of participants with adverse events as a measure of safety and tolerability
15 Recruiting Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea
Condition: Dysmenorrhea
Intervention: Drug: EE20/DRSP(BAY86-5300)
Outcome Measures: Number of days with dysmenorrheic pain over 140 days of evaluation period;   Change in Dysmenorrhea score from baseline to period of withdrawal bleeding;   Change of severity of pain Description;   Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period;   Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period;   Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period;   Endometrial thickness;   Number of days with bleeding and spotting over treatment phase
16 Recruiting Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
Condition: Atrial Fibrillation
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Outcome Measures: Adjudicated major bleeding events;   Safety variables will be summarized using descriptivestatistics based on adverse events collection;   All cause mortality;   Adjudicated symptomatic thromboembolic events
17 Recruiting Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
Condition: Heart Failure
Interventions: Drug: Placebo (treatment 1);   Drug: BAY1067197 (treatment 2)
Outcome Measures: Number of patients with occurrence of AV-Block > I°;   Pharmacokinetic profile determined by tmax;   Pharmacokinetic profile determined by t1/2;   Heart rate;   Blood pressure;   Number of participants with adverse events as a measure of safety and tolerability
18 Recruiting Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea
Condition: Contraception
Intervention: Drug: EV/DNG (Qlaira, BAY86-5027)
Outcome Measures: Incidence of ocular adverse events(AEs) including serious adverse events (SAEs) and Adverse Drug Reactions (ADRs);   Contraceptive Efficacy by Number of unintended pregnancies;   Contraceptive Efficacy by Compliance with Qlaira taking : Administered tablet number/prescribed tablet number;   The relief of heavy menstrual bleeding symptom also will be calculated as an efficacy variable from admission to the study until final visit by subject's assessment
19 Recruiting Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Condition: Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Outcome Measures: Adverse event collection;   Maximum tolerated dose, measured by adverse event profile;   Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed);   Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only);   Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15;   Number of patients with mutational status;   Tumor Response as measured by RECIST 1.1 criteria
20 Recruiting Regulatory Post Marketing Surveillance Study on Nexavar®
Conditions: Carcinoma, Hepatocellular;   Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Outcome Measures: Adverse events collection;   Duration of treatment, dosage and indication;   Tumor status;   Performance status

These studies may lead to new treatments and are adding insight into Bayer etiology and treatment.

A major focus of Bayer research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Bayer